drugset / Trial / NCT01124760

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

NCT01124760

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The aim of this study is to examine the effect of coadministration of CYP3A4 inhibitors on the pharmacokinetics of AZD9742.

Timeline

Start
2010-05
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9742 Unknown 150 mg Intravenous
Subject Diltiazem Small molecule Oral
Subject Ketoconazole Small molecule 200 mg Oral

Indications

No indication recorded.